Background: The potential of TAS-108 for the treatment of breast cancer has been shown by preclinical studies. We therefore investigated the safe dosage, tolerability, and effectiveness on hormone levels and bone metabolism markers and the pharmacokinetics of TAS-108 administered in postmenopausal Japanese women with metastatic breast cancer.
introduction Tamoxifen, a selective estrogen receptor modulator (SERM), has been widely used in pre-and postmenopausal women with hormone receptor-positive advanced breast cancer for the past three decades and is also used for adjuvant therapy after surgery for breast cancer [1] [2] [3] [4] . Recently, endoxifen, a primary active metabolite of tamoxifen, has been reported to be biotransformed by CYP2D6 enzyme, but that those individuals with breast cancer possessing CYP2D6 polymorphism may have shorter relapse-free survival and time to progression [5, 6] . This suggests the importance of the pharmacokinetic profiles of SERMs.
TAS-108, (7a)-21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate, is a novel steroidal antiestrogen compound mainly metabolized by CYP3A4, which has been shown to bind strongly to estrogen receptor (ER)a and ERb, with modes of action unlike tamoxifen and fulvestrant in molecular biological studies [7, 8] . Preclinical and animal studies reported that TAS-108 was effective against estrogen-dependent tumors and also against tamoxifenresistant tumors, with a positive effect on bone mineral density and lower pathological effect on endometrial tissue than tamoxifen [7, 9] . Therefore, TAS-108 may have potential for the treatment of breast cancer.
In the United States, phase I studies have been carried out in healthy postmenopausal women and in postmenopausal women with metastatic breast cancer [10, 11] . TAS-108 was well tolerated up to doses of 160 mg with repeated oral administration. In terms of efficacy, TAS-108 achieved stable disease (SD) at all doses of 40-160 mg, suggesting possible antitumor activity in that range [11] . This study also established that TAS-108 has a linear pharmacokinetic profile with respect to C max [11] .
Our study was a first phase I repeated-dose clinical study in Japan involving postmenopausal patients with breast cancer. We sought to establish safe dose levels, tolerability, effects on hormone levels and bone metabolism markers, and the pharmacokinetics of TAS-108, in which the doses of TAS-108 (40, 80, and 120 mg) were tested on the basis of tolerability, efficacy, and pharmacokinetic data from prior studies on healthy women and breast cancer patients.
patients and methods

patients and study design
We enrolled 16 postmenopausal patients aged 50-78 years with histologically or cytologically confirmed locally advanced or metastatic breast cancer. The postmenopausal status was defined as being amenorrheic for at least 1 year (except for luteinizing hormone-releasing hormone agonist-induced amenorrhea) or having had a hysterectomy and with both serum 17b-estradiol and follicle-stimulating hormone (FSH) levels in the postmenopausal range. All patients had ER-positive and/or progesterone receptor-positive breast cancer and at least one measurable lesion or bone metastasis. Patients had to have received prior standard endocrine therapy which had been terminated at least 2 weeks before starting the treatment. Prior chemotherapy was allowed if it had been stopped for at least 3 weeks before initiating the present treatment. Additional eligibility requirements included adequate organ function [i.e. leukocyte count £10 000/ll, absolute granulocyte count ‡1500/ll, platelet count ‡75 000/ll, hemoglobin ‡9.0 g/dl, total bilirubin and creatinine £1.5-fold the upper limit of normal (ULN), aspartate aminotransferase, alanine aminotransferase (ALT) and alkaline phosphatase £2.5-fold the ULN (except for patients with liver or bone metastasis who could have £5-fold the ULN)]; a predicted life expectancy of ‡3 months; performance status (PS) of two or less on the Zubrod scale.
Patients were ineligible if they had allergy to drugs; past serious thromboembolism; current serious complication(s); active double cancer; lung metastasis with cancer-related lymphangitis and brain metastasis with any symptoms; only one lesion and that lesion had been treated with radiotherapy. Written informed consent was obtained from all patients. The study was approved by the institutional review boards of each participating centre.
In this phase I, open-label, nonrandomized study, patients repeatedly took TAS-108 (in units of 40 mg tablets, Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) orally once a day after the first meal of the day. Eight-week administration was scheduled, but drug treatment was terminated if progression of disease (PD) was observed during the period. After week 8, the drug treatment could be continued if complete response (CR), partial response (PR), or SD had been confirmed. Patients were enrolled in one of three dose groups (40, 80, and 120 mg; five patients per group). If no drugrelated grade 3 or more severe adverse event (AE) was observed in the first 14 days of treatment in the first five patients, the enrollment of patients in the next dose level was permitted. If similar serious drug-related AEs were observed in two patients or more, enrollment in the next dose level was to be cancelled.
On each visit to the outpatient clinic, patients were given a physical examination. We evaluated results of laboratory examinations (at baseline and every week), vital signs (at baseline and every 2 weeks), and performed electrocardiography (at baseline and week 2). Hormones [testosterone, FSH, thyroid-stimulating hormone, cortisol, prolactin, estrone, 17b-estradiol, estriol, luteinizing hormone, and sex hormonebinding globulin (SHBG)] and bone metabolism markers [serum osteocalcin and cross-linked carboxy-terminal telopeptide of type I collagen (ICTP)] were assessed at baseline, week 4, and week 8. Endometrial thickness was measured by transvaginal ultrasonography at baseline and week 8. The above examinations were also assessed at the end of the study and at regular intervals when the drug treatment continued >8 weeks.
end points
The primary end point was to investigate the safe dosage and tolerance of TAS-108 administered in postmenopausal Japanese women with metastatic breast cancer subsequent to standard endocrine therapies. In this study, the following secondary end points were also evaluated; effects on hormone levels and bone metabolism markers, tumor assessment, and pharmacokinetics of TAS-108 and its metabolites (deEt-TAS-108, TAS-108-COOH and O-Me-deEt-TAS-108) in human plasma.
safety and efficacy evaluations
Safety assessments were made according to the National Cancer Institute-Common Toxicity Criteria (by Japan Clinical Oncology Group, v2.0). Patients were assessed every 4 weeks using the Response Evaluation Criteria in Solid Tumors criteria after initiation of TAS-108 treatment. Patients with evaluable lesions which were not measurable, such as bone metastasis, were assessed using the General Rules for Clinical and Pathological Recording of Breast Cancer (14th edition) [12] . The clinical benefit rate was determined by the total number of eligible patients who achieved a CR or PR plus those who had SD for at least 24 weeks. CR was defined as the disappearance of all known lesions for at least 4 weeks. PR was defined as at least a 30% decrease in the sum of the longest diameters of all measurable lesions.
pharmacokinetics
On the day of initiation of treatment, blood samples (3 ml) were collected for measurements of TAS-108 and its metabolites in plasma at predose and 4 h after the first administration. In addition, blood samples were obtained before administration of TAS-108 on one day each in weeks 1, 2, 4, and 8 during treatment. Blood samples were collected into ice-cooled sodium heparin tubes. Plasma was obtained by centrifugation (1900 g) and then stored at 270°C until analysis. Plasma concentrations of TAS-108 and its metabolites were analyzed with validated methods by liquid chromatographic method with tandem mass spectrometric detection.
results
patient characteristics
Of the 16 patients enrolled, we treated 15 with TAS-108. One patient was ineligible because she had not been off endocrine therapy for at least 2 weeks before entry into the study and therefore did not receive treatment with TAS-108. Equal numbers of the remaining patients were allocated to three different dose groups (40, 80, and 120 mg). All but one patient had recurrent breast cancer (Table 1) . There was no patient with only bone metastasis. Fifteen enrolled patients had previously received an average of three endocrine therapy and one chemotherapy regimens. Eleven patients had a PS of zero and the remaining had a PS of one. All patients were ER positive.
safety
Throughout the treatment period, drug-related AEs (definite, probable, possible) were observed in eight patients. They included three grade 2 AEs and 12 grade 1 AEs (Table 2 ). No grade 3 or more severe AEs were observed. The severity of the AEs was unrelated to the dose level of TAS-108.
There were no notable changes over the course of the study in hormone levels and bone metabolism markers (Figure 1 ). We measured endometrial thickness ultrasonographically in 13 patients (Figure 1 ). Of these patients, one in the 80-mg dose group had endometrial hyperplasia after 6 weeks of Annals of Oncology original article administration. This single case had received tamoxifen as adjuvant therapy, and tamoxifen-induced endometrial hyperplasia was observed at the time of relapse. The treatment for recurrence or metastatic disease was sequential treatment of anastrozole and medroxyprogesterone acetate (MPA), and some withdrawal bleeding due to MPA treatment might naturally occur. At the beginning of our study, we performed ultrasonography, but this could not reveal the original baseline thickness before tamoxifen or MPA treatment. The subsequent hyperplasia was considered to be possibly related to TAS-108 intake.
pharmacokinetics
The plasma levels of TAS-108 and its metabolites, deEt-TAS-108, TAS-108-COOH, and O-Me-deEt-TAS-108, increased in a dose-dependent manner, although the mean plasma concentrations of deEt-TAS-108 at a dose of 80 mg at 4 h after the first administration were slightly higher than those receiving a dose of 120 mg due to individual variability (Table 3) . Based on the mean minimum concentration profiles of TAS-108 and its metabolites, deEt-TAS-108 and TAS-108-COOH, the steady state was estimated to be achieved by 2 weeks in each dose group, indicating that there was no remarkable accumulation of TAS-108 and its metabolites. The plasma concentration of O-Me-deEt-TAS-108 approximately doubled at week 8 relative to that at week 1 after the first administration at each dose of TAS-108. efficacy PR was seen in two patients, SD in nine patients, in three of which, SD findings continued for at least 24 weeks, PD in three patients and not evaluable in one patient. One patient each in the 40-mg and 120-mg dose groups showed PR, while two patients in the 40-mg dose group and one patient in the 80-mg dose group showed SD for at least 24 weeks ( Table 4 ). The overall clinical benefit rate for all dosages was 33.3%.
discussion
We set out to determine whether repeated oral administration of TAS-108 at the dose levels tested in this study was well tolerated with efficacy in postmenopausal Japanese patients All data represent mean values (SD). Below the quantitation limit were presumed to be 0.0000 ng/ml. The quantitation limit was 0.1000 ng/ml for TAS-108, deEt-TAS-108 and O-Me-deEt-TAS-108 and 0.5000 ng/ml for TAS-108-COOH. a n = 5 patients for each group except for the number of patients at 8 weeks (n = 3).
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with metastatic breast cancer that had progressed subsequent to previous standard endocrine therapy. In terms of safety, eight patients had mild (grades 1-2) drugrelated AEs, mainly involving hot flashes, arthralgia, and ALT increase. There was no grade 3 or more severe drug-related AE. Blakely et al. [11] reported the pattern of AEs in a phase I study of TAS-108 in which the major AEs included hot flashes, headache, and nausea, which were similar to those associated with other SERMs such as tamoxifen. The pattern of AEs observed in this study was also similar to that in the report by Blakely et al. i.e. there was with no relationship to dose. TAS-108 did not cause notable changes of hormone levels (such as FSH, SHBG), while it was reported that tamoxifen caused those changes in the clinical trials [13] . This observation suggests that TAS-108 may have lower estrogenic effects on hypothalamus-pituitary axis and on the liver, unlike tamoxifen. In addition, thromboembolic events associated with tamoxifen treatment [14, 15] were not seen in this study. Aromatase inhibitors (AIs) have shown improved efficacy over tamoxifen and are recommended as both first-line therapy for advanced breast cancer and in the adjuvant setting for the treatment of early breast cancer [16] [17] [18] . However, breast cancer patients receiving AIs have a higher incidence of osteoporosis, bone fracture, and arthralgia, which can result in discontinuation of treatment [19, 20] . Bone toxicity was not seen in this study which likely reflects the positive effects on bone metabolism reported in animal study [9] . Furthermore, remarkable changes in bone metabolism markers were not seen. The arthralgia experienced by 2 of 15 patients was not clinically significant; the patients had mild symptoms (grade 1 or 2) and soon recovered without any additional medications. Endometrial hyperplasia was recorded in one patient as drug-related AE, but it is unclear whether the event was completely attributable to TAS-108 considering the effects of previous treatments with tamoxifen and MPA on her endometrium (see 'Results'). It has been reported that tamoxifen has unfavorable endometrial effects in Caucasian and Japanese patients. On the other hand, TAS-108 was reported to have no effect on the endometrial lining in the previous clinical study by Blakely et al. [11] and had lower uterotrophic effects than tamoxifen in an animal study [7, 9] . Therefore, TAS-108 was anticipated to have a low risk of endometrial hyperplasia. However, further study is necessary to determine the effect of the long-term use of TAS-108 treatment on the endometrium in a greater number of cases.
In pharmacokinetics, the plasma concentration of TAS-108 at 4 h following administration after food intake in this study was similar to the C max of TAS-108 in Caucasian patients; therefore, it was suggested that the results of exposure to TAS-108 in Japanese patients were not extremely different from that in Caucasian patients. Based on the mean time-minimum concentration profiles of TAS-108 and its metabolites after repeated TAS-108 administration in each dose group in the present study, a steady state was estimated in the pharmacokinetics of TAS-108 to be achieved by 2 weeks, suggesting no remarkable accumulation of TAS-108 and its metabolites.
Two patients achieved PR in the 40-and 120-mg dose groups, and three patients achieved SD for at least 24 weeks in the 40-and 80-mg dose group. Although the sample size of this study was not large enough to establish dose response, TAS-108 had antitumor activity with a total clinical benefit rate of 33.3% in patients who had been heavily treated previously with an average of three endocrine therapy and one chemotherapy regimen. In addition, the majority of patients had received tamoxifen therapy which also had failed. There were 13 patients who had received tamoxifen in the adjuvant treatment and/or treatment for advanced or recurrent breast cancer, and it was encouraging that two achieved PR and two SD for at least 24 weeks.
TAS-108 at all dose levels was well tolerated with no unacceptable toxicity and had antitumor activity in postmenopausal Japanese patients with metastatic breast cancer. A multiinstitutional phase II study to identify the optimal dose of TAS-108 in postmenopausal Japanese women with metastatic breast cancer is in progress. 
